Kura Oncology, Inc. filings document a Nasdaq-listed biopharmaceutical company focused on precision medicines for cancer, including disclosures on KOMZIFTI™ (ziftomenib), acute myeloid leukemia programs, darlifarnib (KO-2806) and collaboration activity with Kyowa Kirin. Form 8-K reports cover financial results, FDA approval and product-launch disclosures, clinical program updates, milestone payments and other material events.
Governance filings include the company’s definitive proxy statement for annual meeting matters, director elections, auditor ratification and executive compensation. Other filings describe amendments to bylaws, the 2023 Inducement Option Plan, nonstatutory stock option grants and the company’s common stock listing on The Nasdaq Global Select Market.
Form 144 notice summary: This filing reports a proposed sale of 4,541 shares of Kura Oncology common stock on NASDAQ through Morgan Stanley Smith Barney LLC on 09/29/2025. The shares were acquired as PSUs from the issuer on 09/27/2025. The filing lists an aggregate market value of $41,096.05 based on reported figures and shows 87,015,518 shares outstanding. The filer reports no securities sold in the past three months and includes the standard attestation regarding absence of undisclosed material information.
Kura Oncology (KURA) Form 144 notice reports a proposed sale of 36,615 shares of common stock, to be executed on 09/29/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The shares were acquired as PSUs from the issuer on 09/27/2025 and carry an aggregate market value of $331,365.75 based on the filing. The filing states there were no securities sold by the reporting person in the prior three months.
The notice includes the standard representation that the seller does not possess any undisclosed material adverse information about the issuer and references Rule 10b5-1 plan disclosure as applicable. No other financial results, holdings, or related-party details are provided in the document.
Kura Oncology (KURA) Form 144 notice states that an individual proposes to sell 8,891 shares of common stock on or about 09/29/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing reports an aggregate market value of $80,463.55 and total shares outstanding of 87,015,518. The shares were acquired as RSUs from the issuer on 09/27/2025 and are listed as payable on 09/29/2025. The filer reports no sales of the issuer's securities in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.
Kura Oncology (KURA) filed a Form 144 reporting a proposed sale of 6,892 shares of common stock through Morgan Stanley Smith Barney LLC on 09/29/2025. The filing lists the aggregate market value of the shares as $62,372.60 and indicates 87,015,518 shares outstanding. The securities were acquired as PSUs from the issuer on 09/27/2025, with payment noted on 09/29/2025. The filer reported no securities sold in the past three months and certified they are unaware of undisclosed material adverse information. Other filer contact fields in the form are present but contain no substantive names or contact details.
Brian T. Powl, Chief Commercial Officer and director at Kura Oncology (KURA), reported receipt of 48,900 shares of common stock from a vesting equity award on 09/27/2025 at no cash price, increasing his beneficial ownership to 108,567 shares. On 09/29/2025 he sold 8,891 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes related to the vesting, leaving him with 99,676 shares beneficially owned. The Form 4 was submitted by a single reporting person and includes an attorney-in-fact signature on behalf of the reporting person.
Teresa Brophy Bair, Chief Legal Officer and director of Kura Oncology, reported two transactions tied to performance-based restricted stock units. On September 27, 2025 1/6th of PSUs vested after the company determined that one specified development milestone was met, resulting in the acquisition of 48,900 shares at a $0 price and increasing her beneficial ownership to 156,848 shares. On September 29, 2025 she executed a sell-to-cover tax transaction, selling 8,805 shares at $8.9422 per share, leaving 148,043 shares beneficially owned. The Form 4 was signed by an attorney-in-fact, Thomas Doyle, on September 29, 2025.
Kathleen Ford, Chief Operating Officer of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units after one development milestone was met on 09/27/2025. The filing shows acquisition by vesting of 48,900 shares (price $0) which increased her beneficial ownership to 70,267 shares, followed by a sell-to-cover transaction of 6,892 shares on 09/29/2025 at $8.9422 per share, leaving 63,375 shares beneficially owned. The sale is disclosed as tax withholding related to the vesting of 1/6th of the underlying PSUs from a grant dated 05/31/2023.
Kura Oncology Chief Medical Officer Mollie Leoni received 82,500 shares of common stock upon vesting of performance-based restricted stock units tied to a development milestone achieved on 09/27/2025. Immediately following, 12,314 shares were sold on 09/29/2025 at a price of $8.9422 per share to cover taxes, leaving the reporting person with 158,439 shares beneficially owned. The filing states each PSU converts to one share if performance and service conditions are met; 1/6th of the grant vested when a milestone was met. Transactions were reported on a Form 4 by one reporting person.
Troy E. Wilson, President and CEO and a director of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units and a related sell-to-cover tax sale. On 09/27/2025 182,500 shares were acquired upon the vesting of 1/6th of PSUs granted May 31, 2023 (price reported $0). On 09/29/2025 the reporting person sold 36,615 shares at $8.9422 per share to cover taxes, leaving 246,853 shares held directly. The filing also shows 279,194 shares held indirectly by One Fish Two Fish Revocable Trust and 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust.
Kura Oncology SVP, Finance & Accounting Thomas Doyle acquired 24,966 shares of Kura common stock on 09/27/2025 at a reported price of $0, increasing his direct holdings to 114,370 shares. On 09/29/2025 he sold 4,541 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes tied to the vesting of 1/6th of performance-based restricted stock units (PSUs). The filing notes that one performance milestone was achieved on 09/27/2025, triggering the vesting event for that tranche; the Reporting Person also reports 500 shares indirectly held in a spouse's 401(k). After the transactions the Reporting Person beneficially owns 109,829 shares.